Inocyte (INCY) - Q4 2025 Review
Wave 3 or Value Trap? Incyte After Q4
Biotech
Novo Nordisk (NVO) - Q4 2025 Review
DISCLAIMER: This note is intended for US recipients only and,
Regeneron (REGN) – Q4 2025 Review
The Pipeline's Gotta Hold!
Arbutus Biopharma (ABUS) - Clinical-Stage, IP-Centric Biopharma
A Binary Biotech Play?
Particles, Patents, Pandemics, and Plaintiffs
What Lies Beneath
Incyte (INCY) – Q3 - 2025 Review
Another Pharma Patent Cliff Rebuild Story?
Pfizer ( PFE ) – Q3 2025 Review
The Stock That Fell To Earth
Q: Is There A Generational Opportunity In Biotech Stocks?
Biotech 2026 = Tech 2023?
Regeneron (REGN) – Q3 2025 Review
Eyeing A Breakout?
Novo Nordisk (NVO) - Q3 FY12/25 Earnings Review
Definitely Some Hair On This One